{"id":"aat","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":{"setId":"526d626f-8c9f-496c-b838-00a73bb36383","title":"YUFLYMA (ADALIMUMAB-AATY) KIT [CELLTRION USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alpha-1 antitrypsin deficiency leads to unopposed neutrophil elastase activity in the lungs, causing progressive tissue destruction. AAT therapy restores the protease-antiprotease balance by supplying exogenous alpha-1 antitrypsin, which inhibits neutrophil elastase and other serine proteases, thereby slowing lung parenchymal damage and decline in pulmonary function.","oneSentence":"AAT (Alpha-1 Antitrypsin) is a protease inhibitor that replaces deficient endogenous alpha-1 antitrypsin to protect lung tissue from enzymatic degradation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:07.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT00001532","phase":"","title":"Role of Genetic Factors in the Development of Lung Disease","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1996-09-13","conditions":"Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis","enrollment":3500},{"nctId":"NCT06186492","phase":"PHASE1","title":"A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)","status":"COMPLETED","sponsor":"Wave Life Sciences Ltd.","startDate":"2023-11-14","conditions":"Alpha-1 Antitrypsin Deficiency (AATD)","enrollment":47},{"nctId":"NCT06389877","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)","status":"RECRUITING","sponsor":"Beam Therapeutics Inc.","startDate":"2024-06-19","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":106},{"nctId":"NCT06624514","phase":"NA","title":"mHealth Behavior Study","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2025-01-29","conditions":"Alcohol Consumption, Condom Use","enrollment":46},{"nctId":"NCT05847478","phase":"NA","title":"Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-06-07","conditions":"Obesity, Childhood","enrollment":240},{"nctId":"NCT06996756","phase":"PHASE1","title":"Gene Therapy for Alpha 1- Antitrypsin Deficiency","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-02-26","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":16},{"nctId":"NCT07431112","phase":"PHASE1","title":"A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)","status":"RECRUITING","sponsor":"AIRNA Corporation","startDate":"2026-02-27","conditions":"Alpha 1 Antitrypsin Deficiency","enrollment":54},{"nctId":"NCT04953910","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2022-12-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":27},{"nctId":"NCT05736718","phase":"NA","title":"Engaging Clinical Champions to Improve HPV Vaccination","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-03-08","conditions":"Human Papilloma Virus","enrollment":47},{"nctId":"NCT07326592","phase":"PHASE4","title":"Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)","status":"NOT_YET_RECRUITING","sponsor":"CSL Behring","startDate":"2026-04-15","conditions":"Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema","enrollment":270},{"nctId":"NCT06165341","phase":"PHASE3","title":"Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-03-01","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":50},{"nctId":"NCT05677971","phase":"PHASE3","title":"Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-03-06","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":160},{"nctId":"NCT01983241","phase":"PHASE3","title":"Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2013-11","conditions":"Pulmonary Emphysema in Alpha-1 PI Deficiency","enrollment":345},{"nctId":"NCT02796937","phase":"PHASE3","title":"Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency","status":"ENROLLING_BY_INVITATION","sponsor":"Grifols Therapeutics LLC","startDate":"2016-07","conditions":"Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency","enrollment":290},{"nctId":"NCT07442552","phase":"","title":"Perioperative Sepsis. An Epigenetic Perspective","status":"RECRUITING","sponsor":"Carol Davila University of Medicine and Pharmacy","startDate":"2026-01-20","conditions":"Sepsis Abdominal","enrollment":40},{"nctId":"NCT07025772","phase":"NA","title":"Shaping Habitual Impulses For a Tobacco-free Style","status":"NOT_YET_RECRUITING","sponsor":"University of Houston","startDate":"2026-03-09","conditions":"ST+ABR, ST+SHAM, ST-only","enrollment":300},{"nctId":"NCT05550844","phase":"","title":"Emphysema and FLNA Mutation (E-FLNA)","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2023-02-01","conditions":"Emphysema","enrollment":8},{"nctId":"NCT07377786","phase":"","title":"Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-02-01","conditions":"HELLP Syndrome","enrollment":60},{"nctId":"NCT06114498","phase":"","title":"Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2023-09-01","conditions":"Heart Failure With Preserved Ejection Fraction, Obesity, Mild, Decompensated Heart Failure","enrollment":240},{"nctId":"NCT05297812","phase":"","title":"Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2022-03-23","conditions":"Alpha 1-Antitrypsin Deficiency, Genetic Disease","enrollment":286},{"nctId":"NCT06505603","phase":"","title":"PiMZ Longitudinal Cohort (PiMZ Logic)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-05-30","conditions":"Alpha 1-Antitrypsin Deficiency, Emphysema or COPD","enrollment":80},{"nctId":"NCT05569759","phase":"PHASE2","title":"A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)","status":"COMPLETED","sponsor":"Kezar Life Sciences, Inc.","startDate":"2023-05-23","conditions":"Autoimmune Hepatitis","enrollment":24},{"nctId":"NCT02363946","phase":"PHASE1","title":"A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":65},{"nctId":"NCT05744960","phase":"NA","title":"Impact of Financial Incentives","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-02-28","conditions":"Human Papilloma Virus","enrollment":34},{"nctId":"NCT07145385","phase":"","title":"Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2026-01","conditions":"Retrospective Cohort of Patients Diagnosed With HCC on Non-Cirrhotic Liver","enrollment":71},{"nctId":"NCT03362242","phase":"PHASE1","title":"Study of ARO-AAT in Normal Adult Volunteers","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2018-03-12","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":45},{"nctId":"NCT01862211","phase":"NA","title":"Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-05","conditions":"Children With a Deficiency of Alpha-1 Antitrypsin","enrollment":296},{"nctId":"NCT02900183","phase":"PHASE2","title":"Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels","status":"WITHDRAWN","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-10","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":""},{"nctId":"NCT06931665","phase":"NA","title":"Neurological and Physiological Effects of Animal-assisted Therapy for Patients in a Minimally Conscious State","status":"RECRUITING","sponsor":"University of Basel","startDate":"2025-07-08","conditions":"Minimally Conscious State","enrollment":26},{"nctId":"NCT05485155","phase":"PHASE2","title":"Zemaira Eosinophilic Esophagitis Pilot Study","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2025-05-15","conditions":"Eosinophilic Esophagitis","enrollment":15},{"nctId":"NCT06677307","phase":"PHASE1, PHASE2","title":"A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110","status":"ACTIVE_NOT_RECRUITING","sponsor":"Korro Bio, Inc.","startDate":"2025-01-13","conditions":"Alpha-1 Anti-trypsin Deficiency, AATD","enrollment":64},{"nctId":"NCT04722887","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2021-08-13","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":17},{"nctId":"NCT04398680","phase":"PHASE1","title":"A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2021-04-20","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT05372029","phase":"NA","title":"AAT for Alcohol Use Disorder in Veterans","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-02-03","conditions":"Alcohol Use Disorder","enrollment":176},{"nctId":"NCT00500123","phase":"","title":"The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2001-01","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":50000},{"nctId":"NCT07242079","phase":"","title":"Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency","status":"COMPLETED","sponsor":"University of Parma","startDate":"2024-11-15","conditions":"Alpha-1 Antitrypsin Deficiency (AATD)","enrollment":50},{"nctId":"NCT06944275","phase":"","title":"Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2026-05-01","conditions":"Haemorrhagic Fever With Renal Syndrome","enrollment":62},{"nctId":"NCT07227207","phase":"PHASE1, PHASE2","title":"A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)","status":"NOT_YET_RECRUITING","sponsor":"Tessera Therapeutics, Inc.","startDate":"2025-12","conditions":"Alpha-1 Antitrypsin Deficiency (AATD)","enrollment":72},{"nctId":"NCT07135427","phase":"PHASE4","title":"Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-09-03","conditions":"Alpha 1-Antitrypsin, COPD, Antibody Deficiency","enrollment":30},{"nctId":"NCT01851642","phase":"","title":"Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs","status":"RECRUITING","sponsor":"University of Florida","startDate":"2007-08-09","conditions":"Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD","enrollment":220},{"nctId":"NCT03805789","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2019-03-27","conditions":"Acute-graft-versus-host Disease","enrollment":222},{"nctId":"NCT03945292","phase":"PHASE2","title":"Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2019-08-07","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":40},{"nctId":"NCT06512454","phase":"","title":"A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-09-25","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":500},{"nctId":"NCT05897424","phase":"PHASE2","title":"Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-06-20","conditions":"Alpha 1-Antitrypsin Deficiency, Emphysema","enrollment":185},{"nctId":"NCT03946449","phase":"PHASE2","title":"Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2019-10-31","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":16},{"nctId":"NCT00571272","phase":"","title":"Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)","status":"SUSPENDED","sponsor":"Arbor Research Collaborative for Health","startDate":"2007-11-30","conditions":"Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency","enrollment":1675},{"nctId":"NCT05899673","phase":"PHASE3","title":"An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-08-08","conditions":"Alpha1-Antitrypsin Deficiency","enrollment":31},{"nctId":"NCT07210931","phase":"NA","title":"Self-managed vs Supervised Exercise for Knee OA","status":"NOT_YET_RECRUITING","sponsor":"Marius Henriksen","startDate":"2025-11-01","conditions":"Knee Osteoarthritis","enrollment":300},{"nctId":"NCT06405633","phase":"PHASE1, PHASE2","title":"A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD","status":"RECRUITING","sponsor":"Wave Life Sciences Ltd.","startDate":"2024-07-19","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":24},{"nctId":"NCT07193615","phase":"EARLY_PHASE1","title":"Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-06-18","conditions":"Alpha-1 Antitrypsin Deficiency (AATD)","enrollment":18},{"nctId":"NCT06468111","phase":"NA","title":"Dog-Assisted Therapy in Children During Blood or Dental Extraction.","status":"RECRUITING","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2022-01-01","conditions":"Emotional Stress","enrollment":120},{"nctId":"NCT06580197","phase":"","title":"The Role of AAT After Abdominal Surgery Based on RWS","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-12-01","conditions":"Acupuncture, Ear, Gastroparesis","enrollment":159},{"nctId":"NCT07167251","phase":"","title":"Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-08-25","conditions":"Immune Related Adverse Events, Immune-Mediated Hepatitis, Cancer","enrollment":63},{"nctId":"NCT06003400","phase":"NA","title":"Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the \"FITT\" Device in Diabetic Foot Ulcers Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tri.O Medical LTD","startDate":"2023-03-29","conditions":"Diabetic Foot Ulcer","enrollment":20},{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":"SLE, Lupus, Systemic Lupus Erthematosus","enrollment":10},{"nctId":"NCT05703893","phase":"","title":"Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2021-11-09","conditions":"Rare Diseases, Aortic Aneurysm, Thoracic","enrollment":139},{"nctId":"NCT07152834","phase":"","title":"Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction","status":"RECRUITING","sponsor":"Muğla Sıtkı Koçman University","startDate":"2025-08-06","conditions":"Alpha 1-antitrypsin Deficiency (AATD)","enrollment":734},{"nctId":"NCT06738017","phase":"PHASE1","title":"Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants","status":"RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2025-02-21","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":12},{"nctId":"NCT05643495","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-02-23","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":14},{"nctId":"NCT04204252","phase":"PHASE3","title":"Phase III, Efficacy and Safety of \"Kamada-AAT for Inhalation\"","status":"RECRUITING","sponsor":"Kamada, Ltd.","startDate":"2019-11-25","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":220},{"nctId":"NCT04167514","phase":"PHASE3","title":"Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2020-01-09","conditions":"Graft Versus Host Disease (GVHD)","enrollment":136},{"nctId":"NCT07144501","phase":"NA","title":"Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09-15","conditions":"Congenital Heart Disease, Liver Dysfunction","enrollment":40},{"nctId":"NCT05693896","phase":"NA","title":"Treating Binge Eating and Obesity Digitally in Black Women","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-01-15","conditions":"Binge Eating, Binge-Eating Disorder, Weight Gain Prevention","enrollment":60},{"nctId":"NCT07125664","phase":"PHASE2","title":"Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2025-10-01","conditions":"Acute Exacerbation Chronic Obstructive Pulmonary Disease","enrollment":36},{"nctId":"NCT02014415","phase":"","title":"Alpha-1 Antitrypsin Deficiency Adult Liver Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Louis University","startDate":"2013-12","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":120},{"nctId":"NCT06387667","phase":"NA","title":"Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","status":"NOT_YET_RECRUITING","sponsor":"New Valley University","startDate":"2025-12-01","conditions":"Immunocompromised ICU Patients With Respiratory Tract Infections","enrollment":250},{"nctId":"NCT03910959","phase":"NA","title":"Therapeutic Effects of Animal-assisted Therapy for Patients in a Minimally Conscious State","status":"COMPLETED","sponsor":"University of Basel","startDate":"2019-07-10","conditions":"Minimally Conscious State","enrollment":30},{"nctId":"NCT05856331","phase":"PHASE2","title":"Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-12","conditions":"Alpha 1-Antitrypsin Deficiency, Emphysema","enrollment":99},{"nctId":"NCT04923256","phase":"NA","title":"AAT-APP+: A Novel Brain-training App to Reduce Drinking","status":"COMPLETED","sponsor":"Turning Point","startDate":"2022-06-30","conditions":"Alcohol Use Disorder","enrollment":188},{"nctId":"NCT06848244","phase":"NA","title":"Preventing Type 2 Diabetes in Black Emergent Adult","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-06-30","conditions":"Type 2 Diabetes Mellitus, Binge-Eating Disorder, Binge Eating","enrollment":100},{"nctId":"NCT06049082","phase":"PHASE1","title":"A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","startDate":"2024-02-15","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":15},{"nctId":"NCT07067606","phase":"","title":"Role of Musculoskeletal Ultrasound for Early Detection of Synovitis in SLE Patient and Its Correlation With Disease Activity and Neutrophil-to-C3 Ratio.","status":"NOT_YET_RECRUITING","sponsor":"Mervat Sayed Kamal Sayed","startDate":"2025-10-30","conditions":"Musckloskeletal US","enrollment":90},{"nctId":"NCT05426460","phase":"NA","title":"AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior","status":"COMPLETED","sponsor":"Cynthia Conklin","startDate":"2022-04-29","conditions":"Smoking Behaviors, Smoking, Cigarette","enrollment":41},{"nctId":"NCT03544632","phase":"PHASE2","title":"Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction","status":"ENROLLING_BY_INVITATION","sponsor":"Johns Hopkins University","startDate":"2018-06-21","conditions":"Soft Tissue Injuries, Trauma","enrollment":15},{"nctId":"NCT02713997","phase":"PHASE4","title":"Anti-inflammatory Therapy to Improve Outcomes After TPIAT","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-12","conditions":"Pancreatitis, Chronic; Diabetes; Transplant","enrollment":43},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT07023159","phase":"","title":"Predicting 28-Day Survival in OHCA Patients","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2023-05-01","conditions":"Out of Hospital Cardiac Arrest, Cardiac Arrest (CA)","enrollment":327},{"nctId":"NCT06812247","phase":"NA","title":"Therapy Dog Visits for Patients Hospitalized With Traumatic Injuries","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-06-04","conditions":"Trauma Injury, Depression, Anxiety","enrollment":80},{"nctId":"NCT02691611","phase":"","title":"Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2015-12","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":39},{"nctId":"NCT05464888","phase":"NA","title":"Animal Assisted Therapy in Pediatric Dentistry","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-02-02","conditions":"Anxiety","enrollment":225},{"nctId":"NCT05742386","phase":"NA","title":"Impact of Standing Orders Optimization","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-02-22","conditions":"Human Papilloma Virus","enrollment":28},{"nctId":"NCT04799873","phase":"","title":"Alpha-1-Antitrypsin-Deficiency in COVID-19","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2020-04-08","conditions":"Covid19","enrollment":10},{"nctId":"NCT05250180","phase":"NA","title":"Animal Assisted Therapy After Pediatric Brain Injury: Mediators and Moderators of Treatment Response.","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-07-22","conditions":"Brain Injuries","enrollment":90},{"nctId":"NCT01808352","phase":"","title":"HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2013-08-15","conditions":"HIV","enrollment":226},{"nctId":"NCT06549712","phase":"NA","title":"The Fondazione Genomic SARS-CoV-2 Study COVID-19","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2020-03-23","conditions":"COVID-19, Genetic Predisposition","enrollment":4000},{"nctId":"NCT06910098","phase":"NA","title":"Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels","status":"COMPLETED","sponsor":"Central Park Medical College","startDate":"2023-12-01","conditions":"LDL - Low Density Lipoprotein Receptor Disorder, Rosuvastatin","enrollment":195},{"nctId":"NCT06892236","phase":"NA","title":"Preparation of IPSC for Cell Gene Editing for the Treatment of AATD","status":"ENROLLING_BY_INVITATION","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2025-01-15","conditions":"Alpha1-antitrypsin Deficiency","enrollment":3},{"nctId":"NCT06582329","phase":"PHASE2","title":"Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"Medical University Innsbruck","startDate":"2025-04","conditions":"Alcohol-Associated Hepatitis","enrollment":16},{"nctId":"NCT04964310","phase":"","title":"Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-08-31","conditions":"Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics","enrollment":339},{"nctId":"NCT04621006","phase":"","title":"The Contact Activation System and Ulcerative Colitis","status":"COMPLETED","sponsor":"Esbjerg Hospital - University Hospital of Southern Denmark","startDate":"2021-05-01","conditions":"Ulcerative Colitis","enrollment":102},{"nctId":"NCT06818149","phase":"","title":"Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-01-30","conditions":"Lung Cancer, Myocarditis Due to Drug","enrollment":50},{"nctId":"NCT06816199","phase":"","title":"The Safety and the Efficiency of Hyperbaric Oxygen in Traumatic Brain Injury","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-20","conditions":"Traumatic Brain Injury","enrollment":300},{"nctId":"NCT06622668","phase":"PHASE1, PHASE2","title":"NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease","status":"WITHDRAWN","sponsor":"Intellia Therapeutics","startDate":"2024-11-20","conditions":"Lung Disease, Pulmonary Disease, AATD","enrollment":""},{"nctId":"NCT05435638","phase":"PHASE1","title":"Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases","status":"COMPLETED","sponsor":"Kamari Pharma Ltd","startDate":"2022-07-17","conditions":"Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita","enrollment":14},{"nctId":"NCT04764448","phase":"PHASE2","title":"A Study of Belcesiran in Patients With AATLD","status":"TERMINATED","sponsor":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","startDate":"2021-02-12","conditions":"Alpha 1-Antitrypsin Deficiency","enrollment":16},{"nctId":"NCT05120856","phase":"NA","title":"AAT-App Outpatient Trial","status":"COMPLETED","sponsor":"Turning Point","startDate":"2022-05-25","conditions":"Alcohol Use Disorder (AUD)","enrollment":82},{"nctId":"NCT02918968","phase":"PHASE4","title":"Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-02","conditions":"Prostate Cancer","enrollment":206},{"nctId":"NCT04932512","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-06-17","conditions":"Steatohepatitis, Nonalcoholic","enrollment":160},{"nctId":"NCT05674643","phase":"","title":"Gastric Assessment of Pediatric Patients Undergoing Surgery","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-02-01","conditions":"Fasting, Delayed Gastric Emptying, Aspiration Pneumonia","enrollment":60},{"nctId":"NCT05671887","phase":"","title":"DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2022-11-16","conditions":"Lung Cancer, Bilateral Cancer, Lung Transplant","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4602,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alpha-1 proteinase inhibitor","Respreeza"],"phase":"marketed","status":"active","brandName":"AAT","genericName":"AAT","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AAT is an alpha-1 antitrypsin replacement therapy that replenishes deficient serum levels of the protease inhibitor to prevent progressive lung and liver damage. Used for Alpha-1 antitrypsin deficiency with emphysema, Alpha-1 antitrypsin deficiency with progressive lung disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}